NatureWise Biotech & Medicals Future Growth
Future criteria checks 0/6
Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de NatureWise Biotech & Medicals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Personal Products earnings growth | 16.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Lacklustre Performance Is Driving NatureWise Biotech & Medicals Corporation's (GTSM:4732) Low P/E
Apr 29A Look At The Intrinsic Value Of NatureWise Biotech & Medicals Corporation (GTSM:4732)
Mar 25Here's Why We Don't Think NatureWise Biotech & Medicals's (GTSM:4732) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 20In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NatureWise Biotech & Medicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2023 | 180 | 16 | 19 | 19 | N/A |
3/31/2023 | 205 | 23 | 16 | 16 | N/A |
12/31/2022 | 229 | 30 | 14 | 14 | N/A |
9/30/2022 | 261 | 46 | 41 | 41 | N/A |
6/30/2022 | 293 | 63 | 68 | 69 | N/A |
3/31/2022 | 271 | 47 | 51 | 51 | N/A |
12/31/2021 | 250 | 31 | 34 | 34 | N/A |
9/30/2021 | 223 | 15 | 31 | 31 | N/A |
6/30/2021 | 197 | 0 | 28 | 29 | N/A |
3/31/2021 | 252 | 33 | 41 | 42 | N/A |
12/31/2020 | 307 | 65 | 54 | 56 | N/A |
9/30/2020 | 330 | 70 | 40 | 42 | N/A |
6/30/2020 | 354 | 76 | 26 | 28 | N/A |
3/31/2020 | 331 | 58 | 19 | 21 | N/A |
12/31/2019 | 307 | 40 | 12 | 13 | N/A |
9/30/2019 | 251 | 19 | -6 | -5 | N/A |
6/30/2019 | 195 | -2 | -24 | -23 | N/A |
3/31/2019 | 152 | -9 | -21 | -20 | N/A |
12/31/2018 | 108 | -15 | -18 | -18 | N/A |
9/30/2018 | 99 | -19 | -26 | -25 | N/A |
6/30/2018 | 90 | -23 | -33 | -32 | N/A |
3/31/2018 | 79 | -42 | -43 | -43 | N/A |
12/31/2017 | 69 | -60 | -54 | -54 | N/A |
9/30/2017 | 65 | -67 | -56 | -55 | N/A |
6/30/2017 | 61 | -74 | -59 | -56 | N/A |
3/31/2017 | 59 | -67 | N/A | -59 | N/A |
12/31/2016 | 58 | -60 | N/A | -62 | N/A |
9/30/2016 | 54 | -46 | N/A | -51 | N/A |
6/30/2016 | 51 | -32 | N/A | -41 | N/A |
3/31/2016 | 51 | -30 | N/A | -36 | N/A |
12/31/2015 | 50 | -29 | N/A | -31 | N/A |
9/30/2015 | 48 | -30 | N/A | -32 | N/A |
6/30/2015 | 45 | -31 | N/A | -33 | N/A |
3/31/2015 | 46 | -29 | N/A | -21 | N/A |
12/31/2014 | 48 | -26 | N/A | -8 | N/A |
9/30/2014 | 52 | -23 | N/A | -2 | N/A |
6/30/2014 | 57 | -20 | N/A | 3 | N/A |
3/31/2014 | 61 | -16 | N/A | -4 | N/A |
12/31/2013 | 65 | -12 | N/A | -12 | N/A |
9/30/2013 | 74 | -13 | N/A | -10 | N/A |
6/30/2013 | 84 | -15 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 4732 es superior a la tasa de ahorro (0.8%).
Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de 4732 crezcan más deprisa que el mercado TW
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 4732 crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 4732 crezcan más rápido que el mercado de TW.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 4732 crezcan a un ritmo superior a 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de 4732 se prevé elevada dentro de 3 años.